In combination with TKI, PKC activators (Bryostatin) have been tested in CML treatment showing a reduction of cell growth and increase of apoptosis [77, 78]. The gene discussed is PRRT2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.